20/20 Biolabs, Inc. — Company profile
Healthcare · Medical Devices · United States
Last price 0.213 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.72M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Details
| Name | 20/20 Biolabs, Inc. |
| Sector | Healthcare |
| Industry | Medical Devices |
| Employees | 14 |
| Founded | 2000 |
| Ceo | Jonathan Cohen |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US90138K1016 |
| Cusip | 90138K101 |
| Cik | 1139685 |
| Sic | 8734 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Jonathan Cohen | Founder, Chief Executive Officer, President and Director |
| Dr. Jiming Zhou Ph.D. | Chief Operating Officer |
| Dr. Michael Saul Lebowitz Ph.D. | Chief Scientific Officer |
| Alan B. Bergman | Chief Financial Officer |
| David Lees | Director of Sales |
| Ronald R. Baker | Chief Business Officer |
| Marc Gordon | Controller |
Contact
| Address | 15810 Gaither Road, Suite 235, Gaithersburg, Maryland 20877, United States |
| Phone | 240 453 6339 |
| Website | https://2020biolabs.com |